ResMed Net Total Equity Issued/Repurchased 2010-2025 | RMD
ResMed annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- ResMed net total equity issued/repurchased for the quarter ending March 31, 2025 was $-0.156B, a 108.74% increase year-over-year.
- ResMed net total equity issued/repurchased for the twelve months ending March 31, 2025 was $-0.384B, a 611.34% increase year-over-year.
- ResMed annual net total equity issued/repurchased for 2024 was $-0.097B, a 297.22% decline from 2023.
- ResMed annual net total equity issued/repurchased for 2023 was $0.049B, a 3.71% increase from 2022.
- ResMed annual net total equity issued/repurchased for 2022 was $0.047B, a 25.39% increase from 2021.
| ResMed Annual Net Total Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $-97 |
| 2023 | $49 |
| 2022 | $47 |
| 2021 | $38 |
| 2020 | $48 |
| 2019 | $14 |
| 2018 | $-15 |
| 2017 | $38 |
| 2016 | $-74 |
| 2015 | $-121 |
| 2014 | $-169 |
| 2013 | $-117 |
| 2012 | $-330 |
| 2011 | $-69 |
| 2010 | $-36 |
| 2009 | $-44 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $35.183B | $4.685B |
| ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. The company currently has two operating segments, which are the Sleep and Respiratory Care segment and the Software-as-a-Service segment. | |||